
    
      Patients with metastatic breast cancer with at least 2 brain metastases, eligible to receive
      SRS. Patients will complete radiation therapy within 1 week and Pembrolizumab may be
      continued every 3 weeks until evidence of brain progression or serious adverse toxicity.
      Patients will be followed until death.

      Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30
      minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
    
  